PD Probiotic

Investigating the effects of B. Subtilis Bacteria on the microbiome in Parkinson’s Disease

This study explores whether a helpful gut bacterium, Bacillus subtilis PXN21, can improve life for people with Parkinson’s disease.

Researchers know that the mix of microbes in the gut (called the gut microbiome) can be different in people with Parkinson’s disease than in those without.

This study looks at whether a helpful gut bacterium, Bacillus subtilis PXN21, can improve life for people with Parkinson’s disease (PD). Researchers know the mix of microbes in the gut—called the gut microbiome—often differs between people with Parkinson’s disease and those without.

Adults with Parkinson’s can join this trial, where they’re randomly placed into two groups. One group takes a pill supplement containing B. subtilis PXN21; the other takes a placebo pill that looks and tastes the same but has no active bacteria. During the study, researchers collect stool samples to track changes in each group’s gut bacteria. They also measure movement symptoms (like tremors and stiffness), thinking skills (such as memory and problem-solving), and everyday activities (like dressing or eating).

The goal is to find out whether B. subtilis PXN21 can improve the microbiome and ease PD symptoms. If the results are promising, this could lead to new gut-focused treatments for Parkinson’s disease.